Rituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage: A case report

Yung Cheng Su; Lee Yung Shih; Chung Chi Huang

doi:10.1016/j.jecm.2011.10.014

Rituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage: A case report

Yung Cheng Su, Lee Yung Shih^*, Chung Chi Huang

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

1 Scopus citations

Abstract

We describe a case of relapsed mantle cell lymphoma receiving four doses of rituximab (375mg/m ²/week) as part of salvage chemotherapy. Acute respiratory distress with hypoxemic respiratory failure requiring ventilatory support was developed 6 weeks after the last dose of rituximab. The findings of microbiological studies did not identify any infectious agents. Bronchoalveolar larvage fluid showed eosinophilia which fulfilled the diagnostic criteria of acute eosinophilic pneumonia. The result of the open lung biopsy showed acute diffuse alveolar damage with interstitial edema, type II pneumocyte hyperplasia and hyaline membrane. Our patient exhibited a new pattern of rituximab-induced lung injury with an excellent and complete response to steroid therapy.

Original language	English
Pages (from-to)	314-317
Number of pages	4
Journal	Journal of Experimental and Clinical Medicine(Taiwan)
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/j.jecm.2011.10.014
State	Published - 12 2011
Externally published	Yes

Keywords

Acute eosinophilic pneumonia
B-cell neoplasm
Diffuse alveolar damage
Drug-induced lung injury
Rituximab

Access to Document

10.1016/j.jecm.2011.10.014

Cite this

@article{e96335b645db43f8aa2535ad3b771efa,

title = "Rituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage: A case report",

abstract = "We describe a case of relapsed mantle cell lymphoma receiving four doses of rituximab (375mg/m 2/week) as part of salvage chemotherapy. Acute respiratory distress with hypoxemic respiratory failure requiring ventilatory support was developed 6 weeks after the last dose of rituximab. The findings of microbiological studies did not identify any infectious agents. Bronchoalveolar larvage fluid showed eosinophilia which fulfilled the diagnostic criteria of acute eosinophilic pneumonia. The result of the open lung biopsy showed acute diffuse alveolar damage with interstitial edema, type II pneumocyte hyperplasia and hyaline membrane. Our patient exhibited a new pattern of rituximab-induced lung injury with an excellent and complete response to steroid therapy.",

keywords = "Acute eosinophilic pneumonia, B-cell neoplasm, Diffuse alveolar damage, Drug-induced lung injury, Rituximab",

author = "Su, {Yung Cheng} and Shih, {Lee Yung} and Huang, {Chung Chi}",

year = "2011",

month = dec,

doi = "10.1016/j.jecm.2011.10.014",

language = "英语",

volume = "3",

pages = "314--317",

journal = "Journal of Experimental and Clinical Medicine(Taiwan)",

issn = "1878-3317",

publisher = "Elsevier Taiwan LLC",

number = "6",

}

TY - JOUR

T1 - Rituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage

T2 - A case report

AU - Su, Yung Cheng

AU - Shih, Lee Yung

AU - Huang, Chung Chi

PY - 2011/12

Y1 - 2011/12

N2 - We describe a case of relapsed mantle cell lymphoma receiving four doses of rituximab (375mg/m 2/week) as part of salvage chemotherapy. Acute respiratory distress with hypoxemic respiratory failure requiring ventilatory support was developed 6 weeks after the last dose of rituximab. The findings of microbiological studies did not identify any infectious agents. Bronchoalveolar larvage fluid showed eosinophilia which fulfilled the diagnostic criteria of acute eosinophilic pneumonia. The result of the open lung biopsy showed acute diffuse alveolar damage with interstitial edema, type II pneumocyte hyperplasia and hyaline membrane. Our patient exhibited a new pattern of rituximab-induced lung injury with an excellent and complete response to steroid therapy.

AB - We describe a case of relapsed mantle cell lymphoma receiving four doses of rituximab (375mg/m 2/week) as part of salvage chemotherapy. Acute respiratory distress with hypoxemic respiratory failure requiring ventilatory support was developed 6 weeks after the last dose of rituximab. The findings of microbiological studies did not identify any infectious agents. Bronchoalveolar larvage fluid showed eosinophilia which fulfilled the diagnostic criteria of acute eosinophilic pneumonia. The result of the open lung biopsy showed acute diffuse alveolar damage with interstitial edema, type II pneumocyte hyperplasia and hyaline membrane. Our patient exhibited a new pattern of rituximab-induced lung injury with an excellent and complete response to steroid therapy.

KW - Acute eosinophilic pneumonia

KW - B-cell neoplasm

KW - Diffuse alveolar damage

KW - Drug-induced lung injury

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=83455213303&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2011.10.014

DO - 10.1016/j.jecm.2011.10.014

M3 - 文章

AN - SCOPUS:83455213303

SN - 1878-3317

VL - 3

SP - 314

EP - 317

JO - Journal of Experimental and Clinical Medicine(Taiwan)

JF - Journal of Experimental and Clinical Medicine(Taiwan)

IS - 6

ER -

Rituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage: A case report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this